Claudin 18.2在大型土耳其队列胃腺癌中的表达

Q4 Medicine Duzce Medical Journal Pub Date : 2023-08-02 DOI:10.47493/abantmedj.1313791
A. Isık, Güneş Güner, Can Zeyneloğlu, Seçil Demirkol Canlı, H. Tastan, Aytekin Akyol
{"title":"Claudin 18.2在大型土耳其队列胃腺癌中的表达","authors":"A. Isık, Güneş Güner, Can Zeyneloğlu, Seçil Demirkol Canlı, H. Tastan, Aytekin Akyol","doi":"10.47493/abantmedj.1313791","DOIUrl":null,"url":null,"abstract":"Background: Claudin 18.2 (CLDN18.2) is a tight junction protein expressed especially in gastric adenocarcinomas. The prognostic and clinicopathologic implications of CLDN18.2 expression is currently unknown. Zolbetuximab monoclonal antibody against CLDN18.2 is under investigation as a potential treatment for advanced gastric cancer (GC). We aimed to investigate the impact of CLDN18.2 expression in GC on prognosis and tumor features in a large Turkish cohort. \nMethods: Seven tissue microarrays (TMAs) containing 263 cases of GC were constructed. Assessment of CLDN18.2 expression was performed by immunohistochemistry, where it was scored as negative and positive. \nResults: 14.3% (37/258) of GCs were stained with anti-CLDN18.2 antibody. While 7.8% (20/258) of all cases were positive, 92.2% (238/258) were scored as negative. There was no statistically significant difference between the two groups in terms of patient features such as age or sex, tumor grade, TNM stage, histologic subtype or overall survival. \nConclusion: CLDN18.2 expression was not associated with patient prognosis in the Turkish cohort. However, as this molecule is a potential therapeutic target, information about the impact of CLDN18.2 expression will be important in managing patients, therefore more studies are needed to learn more on the outcomes of CLDN18.2 expression on clinicopathologic features in GC.","PeriodicalId":53622,"journal":{"name":"Duzce Medical Journal","volume":"45 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Claudin 18.2 Expression in Gastric Adenocarcinomas in a Large Turkish Cohort\",\"authors\":\"A. Isık, Güneş Güner, Can Zeyneloğlu, Seçil Demirkol Canlı, H. Tastan, Aytekin Akyol\",\"doi\":\"10.47493/abantmedj.1313791\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Claudin 18.2 (CLDN18.2) is a tight junction protein expressed especially in gastric adenocarcinomas. The prognostic and clinicopathologic implications of CLDN18.2 expression is currently unknown. Zolbetuximab monoclonal antibody against CLDN18.2 is under investigation as a potential treatment for advanced gastric cancer (GC). We aimed to investigate the impact of CLDN18.2 expression in GC on prognosis and tumor features in a large Turkish cohort. \\nMethods: Seven tissue microarrays (TMAs) containing 263 cases of GC were constructed. Assessment of CLDN18.2 expression was performed by immunohistochemistry, where it was scored as negative and positive. \\nResults: 14.3% (37/258) of GCs were stained with anti-CLDN18.2 antibody. While 7.8% (20/258) of all cases were positive, 92.2% (238/258) were scored as negative. There was no statistically significant difference between the two groups in terms of patient features such as age or sex, tumor grade, TNM stage, histologic subtype or overall survival. \\nConclusion: CLDN18.2 expression was not associated with patient prognosis in the Turkish cohort. However, as this molecule is a potential therapeutic target, information about the impact of CLDN18.2 expression will be important in managing patients, therefore more studies are needed to learn more on the outcomes of CLDN18.2 expression on clinicopathologic features in GC.\",\"PeriodicalId\":53622,\"journal\":{\"name\":\"Duzce Medical Journal\",\"volume\":\"45 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Duzce Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47493/abantmedj.1313791\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Duzce Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47493/abantmedj.1313791","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:Claudin 18.2 (CLDN18.2)是一种在胃腺癌中表达的紧密连接蛋白。目前尚不清楚CLDN18.2表达的预后和临床病理意义。针对CLDN18.2的Zolbetuximab单克隆抗体正在研究作为晚期胃癌(GC)的潜在治疗方法。我们的目的是在一个大型土耳其队列中研究CLDN18.2在胃癌中的表达对预后和肿瘤特征的影响。方法:构建包含263例胃癌的7个组织微阵列(tma)。通过免疫组织化学评估CLDN18.2的表达,并将其评分为阴性和阳性。结果:14.3%(37/258)的GCs被抗cldn18.2抗体染色。阳性占7.8%(20/258),阴性占92.2%(238/258)。两组患者在年龄、性别、肿瘤分级、TNM分期、组织学亚型、总生存期等方面无统计学差异。结论:在土耳其队列中,CLDN18.2的表达与患者预后无关。然而,由于该分子是一个潜在的治疗靶点,关于CLDN18.2表达对患者管理的影响的信息将是重要的,因此需要更多的研究来了解CLDN18.2表达对GC临床病理特征的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Claudin 18.2 Expression in Gastric Adenocarcinomas in a Large Turkish Cohort
Background: Claudin 18.2 (CLDN18.2) is a tight junction protein expressed especially in gastric adenocarcinomas. The prognostic and clinicopathologic implications of CLDN18.2 expression is currently unknown. Zolbetuximab monoclonal antibody against CLDN18.2 is under investigation as a potential treatment for advanced gastric cancer (GC). We aimed to investigate the impact of CLDN18.2 expression in GC on prognosis and tumor features in a large Turkish cohort. Methods: Seven tissue microarrays (TMAs) containing 263 cases of GC were constructed. Assessment of CLDN18.2 expression was performed by immunohistochemistry, where it was scored as negative and positive. Results: 14.3% (37/258) of GCs were stained with anti-CLDN18.2 antibody. While 7.8% (20/258) of all cases were positive, 92.2% (238/258) were scored as negative. There was no statistically significant difference between the two groups in terms of patient features such as age or sex, tumor grade, TNM stage, histologic subtype or overall survival. Conclusion: CLDN18.2 expression was not associated with patient prognosis in the Turkish cohort. However, as this molecule is a potential therapeutic target, information about the impact of CLDN18.2 expression will be important in managing patients, therefore more studies are needed to learn more on the outcomes of CLDN18.2 expression on clinicopathologic features in GC.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Duzce Medical Journal
Duzce Medical Journal Medicine-Medicine (all)
CiteScore
0.60
自引率
0.00%
发文量
59
审稿时长
12 weeks
期刊最新文献
Karotis Stenozu Tedavisinde Karotis Arter Stentleme ve Karotis Endarterektomi Yöntemlerinin Kısa Dönem Sonuçları: Randomize Kontrollü Çalışmaların Güncel Bir Meta-Analizi The Effect of Treatment on Weight Gain in Iron Deficiency Anemia and Its Association with Ghrelin and Hepcidin Levels The Effect of Inflammatory Markers in the Hemogram Parameters of Pregnant Women with Thyroid Disease on Obstetric and Neonatal Outcomes A Rare Manifestation of Leptospirosis: Long-Term Elevation in Liver Enzymes Muscarinic Receptors as Targets for Metronomic Therapy in Ovarian Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1